The Eli Lilly, Pfizer and Sanofi-backed cancer therapy developer raised $150m despite reducing the number of shares in the IPO and floating beneath its range.

BioNTech, a Germany-based immuno-oncology therapy developer backed by pharmaceutical companies Pfizer, Eli Lilly and Sanofi, will go public on the Nasdaq Global Select Market today in a $150m initial public offering. The company priced 10 million American Depositary Shares, each equating to one normal share, at $15.00 this morning, giving it a fully diluted valuation…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.